Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Renalytix ( (GB:RENX) ) has provided an update.
Renalytix has partnered with MVP Health Care to provide its FDA-approved kidneyintelX.dkd test to MVP’s 700,000 members in the northeastern United States. This collaboration aims to enhance early-stage risk assessment for chronic kidney disease in type 2 diabetes patients, allowing for more targeted therapeutic options and improved patient outcomes. The partnership reflects MVP’s commitment to innovative and affordable healthcare solutions, while Renalytix continues to demonstrate its impact on mitigating chronic kidney disease progression and improving health metrics in high-risk patients.
Spark’s Take on GB:RENX Stock
According to Spark, TipRanks’ AI Analyst, GB:RENX is a Underperform.
Renalytix’s overall stock score is low due to severe financial challenges, including declining revenues, high operating losses, and solvency issues. Despite positive corporate events suggesting strategic interest and growth potential, the technical analysis and valuation remain weak, impacting the stock’s appeal.
To see Spark’s full report on GB:RENX stock, click here.
More about Renalytix
Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on optimizing the clinical management of kidney disease to improve patient outcomes. The company has received FDA approval and Medicare reimbursement for its kidneyintelX.dkd test, which is commercially available in the United States.
Average Trading Volume: 111,972
Technical Sentiment Signal: Sell
Current Market Cap: £22.36M
Find detailed analytics on RENX stock on TipRanks’ Stock Analysis page.